We administered aerosolized histamine to 32 subjects with tetraplegia to determine whether there were differences in spirometric and/or lung volume parameters between responders and nonresponders. Results: Baseline pulmonary function parameters revealed mild to moderate restrictive dysfunction. We found that 25 subjects (78%) were hyperreactive to histamine (mean provocative concentration of a substance causing a 20% fall in FEV 1 [PC 20 
T
he majority of subjects with tetraplegia display airway hyperreactivity (AHR) following the inhalation of methacholine, histamine, or ultrasonically nebulized distilled water. [1] [2] [3] [4] One explanation for exaggerated bronchoconstriction among these subjects is reduced resting airway caliber due to the loss of sympathetic innervation originating in the upper six thoracic segments of the spinal cord. Reduced airway caliber and increased airway resistance may play a pivotal role in AHR based on the mathematical theorem that resistance of laminar gas flow is inversely related to the fourth power of the radius. Accordingly, with narrowed airways, a given degree of further narrowing caused by a bronchoconstrictive agent will be associated with greater obstruction to flow than the same degree of narrowing occurring at normal patency. 5 The specific goal of this investigation, therefore, was to determine the relationships between histamine responsiveness and spirometric/lung volume parameters among subjects with chronic tetraplegia.
Materials and Methods
Thirty-two subjects in clinically stable condition with chronic cervical spinal cord injury (tetraplegia) of at least 1-year duration participated in this study. None were receiving medications known to alter responsiveness to histamine. Subjects were selected who reported no preinjury history of pulmonary disease, atopy, or asthma. All denied recent or active pulmonary infections. The study was approved by the Institutional Review Board of the Bronx Veterans Affairs Medical Center, and informed consent was obtained prior to investigation.
Spirometric measurements were obtained while subjects were seated in their wheelchairs (model 2200 Automated Pulmonary Function Laboratory; SensorMedics; Yorba Linda, CA). Baseline values of FVC and FEV 1 were obtained according to the recommendations of the American Thoracic Society. 6 Accordingly, the best FVC and corresponding FEV 1 values from three reproducible FVC maneuvers (Ϯ 5%), each of at least 6-s duration, were obtained. Spirometry results are expressed as absolute values and percent predicted based on the standards of Morris et al. 7 Measures of respiratory muscle strength (ie, maximal inspiratory pressure [Pimax] and maximal expiratory pressure [Pemax]) were obtained using an electronic portable mouth pressure meter (Vacu-Med; Ventura, CA) from the best of three maximum efforts, each beginning from residual volume (RV) and total lung capacity (TLC), respectively. Lung volumes were determined using the open-circuit nitrogen washout technique and were expressed as absolute values and as percent predicted based on the prediction equations of Crapo et al. 8 Histamine challenge consisted of a series of maneuvers, each involving five slow inhalations (inspiratory time, 5 s) from functional residual capacity (FRC) to TLC. Subjects were instructed not to hold their breath at TLC and to exhale slowly. The time between each inhalation was approximately 10 s. Subjects demonstrating a Ͻ 10% response to normal saline solution were challenged with increasing concentrations (ie, 0.025, 0.25, 2.5, 10, and 25 mg/mL) of histamine diphosphate (Freeman Industries; Tuckahoe, NY). Aerosols were generated by a nebulizer (Salter 8900; Asthmakit, Diemolding Healthcare Division; Canastota, NY) driven by air at a flow rate of 8 L/min with an output of 0.35 mL/min. Particle size ranged from 1.6 to 3.4 m. On initiation of each breath, nebulization was performed by manual occlusion of a thumb port for approximately 1.5 s. Spirometry was measured 2 to 3 min after each set of five inhalations, or sooner if dyspnea or chest tightness developed. The challenge was terminated either when the FEV 1 decreased Ն 20% from baseline (ie, a provocative concentration of a substance causing a 20% fall in FEV 1 [PC 20 ]) or when the maximal concentration of histamine (25 mg/mL) was administered. The PC 20 was calculated using a computer program that generated the value by interpolation from a logarithmic dose-response curve. A PC 20 of Ͻ 8 mg/mL defined AHR 9 and separated responders from nonresponders. Subjects with a PC 20 of Ͻ 8 mg/mL and/or symptoms were immediately given an inhaled ␤ 2 -agonist (ie, a 2.5-mL dose of a 0.6% solution of metaproterenol sulfate) and were observed until the symptoms abated and the FEV 1 returned to within 5% of baseline. A PC 20 value of 25 mg/mL was used in the calculations for subjects not responding to the maximal concentration of histamine.
A subgroup who had exhibited AHR underwent, on an alternate day, serial saline solution challenges (single-blind) employing the same protocol used for histamine bronchoprovocation.
All data are expressed as mean Ϯ SD. A natural logarithmic transformation was performed on PC 20 values (lnPC 20 ). An unpaired Student's t test was applied to determine differences between responders and nonresponders for pulmonary function and PC 20 values and to assess differences between subjects responding with a PC 20 of Ͻ 2 mg/mL and those responding with a PC 20 between 2 and 8 mg/mL. Simple regression analysis was used to assess the relationships between PC 20 values and baseline pulmonary function. Statistical significance for all analyses was established at a p value Ͻ 0.05.
Results
Twenty-five of 32 subjects with tetraplegia demonstrated AHR (PC 20 , Ͻ 8 mg/mL) in response to aerosolized histamine (Table 1) . Age, duration of injury, level of injury, and completeness of injury did not differ significantly between responders and nonresponders. Although six of seven nonresponders were never-smokers, eight responders were also never-smokers. Among responders, PC 20 values for never-smokers (mean lnPC 20 , 0.36 mg/mL) were comparable to those of current smokers (mean lnPC 20 , 0.83 mg/mL).
The mean values for pulmonary function parameters demonstrated mild to moderate restrictive dysfunction as defined by decreases in TLC percent predicted, FVC percent predicted, and FEV 1 percent predicted and a normal FEV 1 /FVC ratio ( Table  2) . Compared to nonresponders, responders had significantly lower values for forced expiratory flow between 25% and 75% of the outflow curve (FEF , FEF percent predicted, and FEF 25-75 /FVC ratio ( Table 2) . Regression analysis among all subjects demonstrated significant relationships between lnPC 20 and FEF Table 3 ). Regression analysis approached significance for Pimax and FVC percent predicted (r ϭ 0.46; p ϭ 0.08) and reached significance for FEV 1 percent predicted (r ϭ 0.57; p ϭ 0.03) and FEF percent predicted (r ϭ 0.56; p ϭ 0.03). No relationship was found between Pemax and any of the spirometric parameters. Neither Pimax nor Pemax correlated with lnPC 20 . Other lung volume parameters did not differ significantly between responders and nonresponders (Table 2) or between responders with PC 20 values Ͻ 2 mg/mL and those with PC 20 values between 2 and 8 mg/mL (Table 3) .
Five responders had no demonstrable changes in FEV 1 following serial saline solution challenges (Table 4).
Discussion
We found that 25 of 32 subjects in medically stable condition with chronic tetraplegia were hyperresponsive to aerosolized histamine, with a mean PC 20 of 1.77 mg/mL among responders. The findings confirm previous observations involving fewer subjects that demonstrated that the majority of subjects with tetraplegia display exaggerated bronchoconstriction following inhalation of pharmacologically and physicochemically provocative agents. [1] [2] [3] [4] AHR cannot be attributed to asthma or atopy because subjects were closely screened, and those with a history of these conditions were excluded from study. Also, AHR cannot be ascribed to long-term cigarette use because eight responders were never-smokers, and because, among responders, PC 20 values for never-smokers were comparable to those of current smokers. Moreover, in a previous study 2 using methacholine it was demonstrated that PC 20 values among subjects with tetraplegia were comparable among smokers, ex-smokers, and nonsmokers.
In the current study, a comparison of pulmonary function parameters revealed reductions of FEF 25 20 values among all subjects were associated with spirometric indexes of airway caliber (ie, FEV 1 percent predicted and FEF 25-75 percent predicted; Fig 1, 2) and with a surrogate marker of airway size relative to lung size (ie, FEF 25-75 /FVC ratio; Fig 3) but not with lung volume (ie, FVC percent predicted; Fig 4) . Furthermore, although significant relationships were found between Pimax and both FEV 1 percent predicted and FEF 25-75 percent predicted, the absence of a relationship between lnPC 20 and either Pimax or Pemax indicates that AHR cannot be explained on the basis of reduced lung volumes secondary to respiratory muscle weakness. Nor can respiratory muscle fatigue induced by repeated spirometric maneuvers during histamine challenge account for our findings, since serial saline solution challenges in subjects demonstrating AHR documented no appreciable fall in FEV 1 (Table 4) . In a population-based study, a cross-sectional investigation demonstrated that FEF 25-75 /FVC ratio was significantly associated with airway responsiveness to methacholine after adjustment for age, height, initial FEV 1 level, smoking, eosinophil count, and IgE level. 10 An additional population-based study evaluating the response to eucapneic hyperventilation with cold air found that a low prechallenge FEF /FVC ratio was a significant predictor of response. 11 Similarly, random population studies of healthy children and adults have demonstrated that AHR associated with exposure to methacholine, histamine, or cold air correlated with baseline values of FEF , FEF percent predicted, FEV 1 , FEV 1 percent predicted, and/or FEV 1 /FVC ratio. [12] [13] [14] [15] [16] [17] In one study, AHR was an independent predictor of pulmonary function level after adjustment for age, sex, area of residence, respiratory symptom prevalence, and cigarette use. 17 Furthermore, among subjects with asthma or chronic obstructive lung disease, AHR has been found to correlate with baseline values of FEV 1 , FEV 1 percent predicted, FEF percent predicted, and/or FEV 1 /FVC ratio. 18 -21 It appears, therefore, that AHR among different population groups, including those with tetraplegia, is associated with parameters reflecting reduced baseline airway caliber of central and peripheral airways.
One explanation for reduced baseline airway caliber among subjects with tetraplegia is unopposed parasympathetic (cholinergic) activity due to the interruption of sympathetic innervation of the lung. The sympathetic nerve supply to the lung arises in the upper six thoracic segments of the spinal cord. Postganglionic fibers synapse in the middle and inferior cervical ganglia and in the upper four thoracic ganglia, and they enter the hilum to intermingle with cholinergic nerves that form dense plexuses around airways and vessels. 22 Sympathetic fibers also innervate the smooth muscle layer of the human bronchial tree, with a few fibers reaching the level of secondary bronchi and terminal bronchioles. [23] [24] [25] [26] Sympathetic fibers may modulate airway tone indirectly through interaction with parasympathetic fibers in airway ganglia and directly through the local release of norepinephrine. Support for autonomic imbalance comes from findings that approximately 50% of subjects with chronic tetraplegia exhibited a ‡Indicates n ϭ 12 for responders and n ϭ 3 for nonresponders.
significant bronchodilator response (ie, an increase in FEV 1 of Ն 12% and 200 mL) following inhalation of ipratropium bromide. 27 In addition, there are observations that plasma levels of norepinephrine, which reflect overall sympathetic nerve activity, 22 are significantly reduced. 28 Of possible clinical relevance, among a series of patients who had undergone dorsal sympathectomy, subsequent concomitant decreases in midexpiratory flow and lung volume parameters were attributed to sympathetic denervation. 29 With an increase in baseline resting airway tone due to uninhibited parasympathetic activity, even with a normal load, airway smooth muscle is shortened to lengths below the resting length. 30 Epinephrine released from the adrenal medulla also may regulate baseline airway tone and may induce bronchodilation through interaction with airway smooth muscle adrenergic receptors. 22 Of note, circulating levels of epinephrine among subjects with tetraplegia are significantly reduced, reflecting denervation of the adrenal glands. 28, 31 Among subjects with asthma, although baseline catecholamine levels are normal, the infusion of epinephrine producing circulating levels within the range found with exercise causes dose-related bronchodilation and attenuation of methacholine responsiveness. [32] [33] [34] However, the effect of reduced circulating epinephrine levels on resting airway tone among subjects with tetraplegia is unknown, and it has not been determined whether the infusion of epinephrine modulates airway responsiveness to histamine or methacholine. Additional factors may contribute to decreased baseline airway caliber. A decrease in resting "preload" due to softening of the cartilage in large airways, a loss of lung elastin and collagen, or a reduction in elastic recoil will contribute to airway narrowing. 30 Although it is not known whether structural changes occur in the airways or parenchyma following spinal cord injury, subjects with tetraplegia have reduced elastic recoil pressure. 35 Airway wall thickening or secretions within the airway lumen also could increase baseline resistance and maximal response to agonists. 30 Subjects with tetraplegia have difficulty clearing mucus from their lungs and, in the acute phase, produce excessive amounts of thick airway secretions. 36 Finally, it has been suggested that the failure of periodic inflation with deep inspiration may allow airway smooth muscle to become stiff and noncompliant, thereby contributing to exaggerated airway narrowing. 37, 38 Subjects with tetraplegia have reduced TLC and FVC, 39, 40 and, as observed in the current study, FVC was significantly reduced in those subjects exhibiting the greatest responses to histamine (ie, PC 20 , Ͻ 2 mg/mL), and lnPC 20 among responders correlated with FVC percent predicted. Also, among subjects with amyotrophic lateral sclerosis who have intact sympathetic innervation to the lungs, there is a higher prevalence of AHR among those with reduced FVC. 41 It has not been established, however, among subjects with tetraplegia whether an inability to inhale to the predicted TLC affects resting airway caliber or responsiveness to bronchoconstrictive agents.
The clinical significance of AHR among subjects with tetraplegia is unknown. In a study assessing the prevalence of pulmonary symptoms among subjects with spinal cord injury, 73% with high tetraplegia (ie, injury at C5 and above not requiring mechanical ventilation) and 58% with low tetraplegia (ie, injury at C6 to C8) reported that they regularly experienced shortness of breath at rest or with exertion. 42 Presumably, respiratory muscle weakness is a major factor contributing to the sensation of breathlessness among these individuals. Findings among subjects with high tetraplegia, however, that breathlessness worsened following exposure to cold air, hot air, or secondary cigarette smoke suggest that AHR may contribute to breathlessness. In addition, findings that pretreatment with a ␤-agonist (eg, metaproterenol sulfate) blocked hyperresponsiveness to methacholine or histamine 43 and that metaproterenol sulfate or ipratropium bromide alone caused significant bronchodilation in subjects with tetraplegia (42% and 48%, respectively) 27, 44 suggest that long-term administration of a ␤-agonist or anticholinergic agent might provide symptomatic benefit. To our knowledge, however, no prospective study has been performed among these individuals to assess the therapeutic value of bronchodilator therapy. 
